Published in Blood Weekly, July 26th, 2007
Clinical activity confirmed in CIA, a condition associated with a significant rate (e.g., 40-50 percent) of non-response to recombinant erythropoietin (rhEPO);
Two-thirds of patients enrolled in the study increased their hemoglobin levels by an average of 14g/L of blood and one-third of patients maintained their hemoglobin levels;
All patients enrolled with low levels of white blood cells (neutrophils) achieved...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2007-07-26)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.